2025-10-03 - Analysis Report
Okay, here's an analysis of TG Therapeutics Inc. (TGTX), incorporating the provided data.

## TGTX Stock Analysis (as of 2025-10-02)

**0. Executive Summary:**

This report analyzes TG Therapeutics Inc. (TGTX), a biopharmaceutical company focused on developing treatments for B-cell malignancies and autoimmune diseases. The analysis considers relative performance, technical indicators, recent news, analyst opinions, and financial data to provide a comprehensive overview.

**1. Performance vs. S&P 500 (VOO):**

*   **Ticker:** TGTX
*   **Company:** TG Therapeutics Inc
*   **Description:** TG Therapeutics is a biopharmaceutical company focused on developing treatments for B-cell malignancies and autoimmune diseases.
*   **TGTX Cumulative Return:** 92.81%
*   **VOO Cumulative Return:** 97.56%
*   **Absolute Deviation (Cumulative Returns):** -4.75%
*   **Relative Deviation:** 23.7 (on a scale where historical min/max difference is 0-100)

**Analysis:** TGTX has underperformed the S&P 500, with a cumulative return slightly lagging behind VOO. The Relative Deviation of 23.7 indicates that TGTX's current underperformance is closer to its historical minimum difference compared to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD  | Alpha    | Beta    | Cap(B) |
|------------|----------|------|----------|---------|--------|
| 2015-2017  | -5.0%    | 73.5% | -33.0%   | -0.0    | 1.3    |
| 2016-2018  | -12.0%   | 73.5% | -27.0%   | -0.0    | 0.7    |
| 2017-2019  | 74.0%    | 74.1% | 52.0%    | 0.0     | 1.8    |
| 2018-2020  | 316.0%   | 74.1% | 293.0%   | 0.1     | 8.2    |
| 2019-2021  | 124.0%   | 74.1% | 78.0%    | 0.3     | 3.0    |
| 2020-2022  | -71.0%   | 77.8% | -71.0%   | -0.0    | 1.9    |
| 2021-2023  | -284.0%  | 77.8% | -285.0%  | -1.1    | 2.7    |
| 2022-2024  | 56.0%    | 77.8% | 36.0%    | -1.0    | 4.8    |
| 2023-2025  | 93.0%    | 74.8% | 31.0%    | -0.1    | 5.8    |

**Analysis:**

*   **CAGR:** Fluctuates significantly, indicating high volatility.
*   **MDD:** Consistently high, showing substantial drawdowns.
*   **Alpha:** Highly variable, correlating with periods of both significant outperformance and underperformance. Recent years (2020-2023) show strong negative alpha, indicating underperformance relative to its risk (Beta).
*   **Beta:** Generally low or negative, suggesting TGTX is less correlated with the overall market and might even move in the opposite direction.
*   **Market Cap:** Grew over the period, especially during high-growth years.

**2. Recent Price Action:**

*   **Current Price:** 36.41
*   **Last Market Data:**
    *   **Price:** 36.66
    *   **Previous Close:** 36.56
    *   **Change:** 0.27
*   **5-Day Moving Average:** 35.519
*   **20-Day Moving Average:** 33.0672
*   **60-Day Moving Average:** 32.7476

**Analysis:** The current price is above all three moving averages (5, 20, and 60 days), suggesting an upward trend.  The last market data shows a slight increase compared to the previous close. This reinforces the short-term bullish sentiment.

**3. Market Risk Indicators & Expected Return:**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 75.49 (Overbought)
*   **PPO:** 1.2761
*   **Hybrid Signal:**  cash_0%_Buy 100% of cash (32 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-09-02)
*   **Recent (20-day) Relative Deviation Change:** 2.1 (+, indicating short-term upward movement)
*   **Expected Return:** -93.2% (Long-term relative to S&P 500)

**Analysis:**

*   **MRI:** High investment recommended, suggesting a favorable risk-reward profile based on the model.
*   **RSI:** The RSI is in overbought territory, potentially signaling a pullback.
*   **PPO:** Positive PPO indicates an upward trend in price momentum.
*   **Hybrid Signal:** Suggests a "Buy" recommendation, allocating all available cash, indicating strong conviction.
*   **Relative Deviation Change:** The recent increase supports the short-term upward movement.
*   **Expected Return:**  The significantly negative expected return is concerning.  This suggests the model anticipates substantial underperformance compared to the S&P 500 over the long term, despite the positive short-term indicators.  This could be due to factors not captured by the other indicators.
*   **Last Price change:** 0.27 변동폭이 크지 않아 이슈는 아님

**4. Recent News & Significant Events:**

*   **[2025-10-01]** Argus Research raises target price to $38.00.
*   **[2025-09-24]** Positive 6-year Briumvi data showing 90% of MS patients free from progression.
*   **[2025-09-24]** New Briumvi data: 89.9% of patients with relapsing MS were free from disability progression after 6 years of continuous treatment.
*   **[2025-09-22]** Neuraxpharm participates in ECTRIMS, reinforcing its commitment to multiple sclerosis.
*   **[2025-09-17]** B. Riley raises price target to $55 from $53, maintaining a Buy rating.

**Analysis:** The news is overwhelmingly positive, with analysts raising price targets and strong clinical data for Briumvi. This likely contributes to the recent upward price momentum.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy
*   **Mean Rating:** 1.75 (~Buy)
*   **Opinions:** 6
*   **Target Price (Avg/High/Low):** 40.83 / 55.00 / 11.00
*   **Recent Rating Changes:** Not Available.

**Analysis:** Analyst consensus is strongly bullish, with a mean rating of "Buy." The average target price suggests upside potential.

**5. Recent Earnings Analysis:**

| 날짜       | EPS  | 매출        |
|------------|------|-------------|
| 2025-08-08 | 0.19 | 0.14 B$     |
| 2025-05-09 | 0.03 | 0.12 B$     |
| 2024-11-07 | 0.03 | 0.08 B$     |
| 2024-08-09 | 0.05 | 0.07 B$     |
| 2025-08-08 | 0.05 | 0.07 B$     |

**Analysis:** The most recent EPS (0.19) is significantly higher than previous quarters. Revenue has also been increasing. This positive trend in earnings is likely contributing to investor confidence.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-06-30   | $0.14B  | 86.58%        |
| 2025-03-31   | $0.12B  | 87.14%        |
| 2024-12-31   | $0.11B  | 85.77%        |
| 2024-09-30   | $0.08B  | 88.86%        |
| 2024-06-30   | $0.07B  | 88.70%        |

**Capital and Profitability:**

| Quarter      | Equity  | ROE       |
|--------------|---------|-----------|
| 2025-06-30   | $0.28B  | 10.20%    |
| 2025-03-31   | $0.24B  | 2.13%     |
| 2024-12-31   | $0.22B  | 10.49%    |
| 2024-09-30   | $0.19B  | 2.02%     |
| 2024-06-30   | $0.18B  | 3.87%     |

**Analysis:**

*   **Revenue:**  Consistently increasing over the past year.
*   **Profit Margin:**  Extremely high and relatively stable, indicating strong pricing power.
*   **Equity:**  Growing, suggesting the company is retaining earnings and/or raising capital effectively.
*   **ROE:**  Fluctuates, but the most recent value is strong, indicating efficient use of equity to generate profits.

**7. Overall Assessment:**

TGTX presents a mixed picture.

*   **Positive Factors:** Recent price momentum is strong, supported by positive news, analyst ratings, and improving earnings and financial performance. The Market Risk Indicator suggests favorable risk-reward, and the Hybrid Signal recommends a "Buy."
*   **Negative Factors:** TGTX has underperformed the S&P 500, shows a negative long-term expected return, and the RSI indicates overbought conditions, potentially signaling a short-term pullback. Historically, the stock exhibits high volatility and significant drawdowns, as reflected in the MDD.

**Conclusion:**

TGTX appears to be experiencing a short-term bullish run driven by positive clinical data and analyst sentiment. However, potential investors should be aware of the stock's historical volatility, underperformance relative to the broader market, and the concerning long-term expected return. A deeper investigation into the factors driving the negative long-term outlook is warranted before making any investment decisions. While short-term gains are possible, the long-term prospects appear uncertain.
